Business Context and Reporting Period
This Form 8-K was filed by NextCure, Inc. on January 13, 2020, reporting an event that occurred on January 10, 2020. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Beltsville, Maryland. Its common stock trades on the Nasdaq Global Select Market under the symbol NXTC.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change reported is the termination of a significant business agreement:
- Event: Termination of a Material Definitive Agreement (Item 1.02).
- Counterparty: Eli Lilly and Company ("Lilly").
- Agreement: Research and Development Collaboration Agreement dated November 2, 2018.
- Effective Date: The termination is effective as of March 3, 2020.
- Notification Date: NextCure was notified of the termination on January 10, 2020.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the immediate impact of the agreement termination. The document references the terms of the terminated agreement as described in the Company's final prospectus dated November 14, 2019, but does not elaborate on the financial consequences or contingencies within this specific report.
Investor Verification Checklist
- Verify the specific financial terms and milestone payments associated with the terminated Lilly agreement in the November 14, 2019 final prospectus.
- Assess the impact of the March 3, 2020 termination date on the company's projected cash burn and runway.
- Review subsequent filings for any litigation or dispute regarding the termination.
- Confirm if the company has secured alternative funding or partnerships to replace the lost collaboration.